TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers

A Multicenter, Randomized, Single-Blind Study Comparing the Clinical Outcomes of TruSkin® and an Active Comparator for the Treatment of Chronic Venous Leg Ulcers

The purpose of this study is to compare the clinical outcomes of TruSkin® and an Active Comparator in patients with chronic venous leg ulcers.

Study Overview

• Status: Terminated
• Conditions: Chronic Venous Leg Ulcers
• Intervention / Treatment: Other: Wound Cover; Other: TruSkin

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • California
    • California, California, United States
  • Florida
    • Florida, Florida, United States
  • Massachusetts
    • Massachusetts, Massachusetts, United States
  • Michigan
    • Michigan, Michigan, United States
  • North Carolina
    • North Carolina, North Carolina, United States
  • Pennsylvania
    • Pennsylvania, Pennsylvania, United States
  • Virginia
    • Virginia, Virginia, United States

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Between 18 years and 80 years of age inclusive, as of the date of screening
2. An Index Ulcer that is chronic (defined as present for > 4 weeks, but not present for more than 52 weeks at the Screening Visit)
3. Index Ulcer is located on the leg, below the knee
4. The Index Ulcer is a Venous Leg Ulcer (VLU) greater than 10 cm2, inclusive, at the Screening Visit
5. The longest length and longest width measurements for the Index Ulcer are no less than 1 cm each at the Screening Visit
6. The Index Ulcer extends into the dermis or subcutaneous tissue without evidence of exposed muscle, tendon, bone, or joint capsule
7. Wound is free of necrotic debris
8. Patient has adequate circulation to the foot as documented by Ankle Brachial Index (ABI) or Toe Brachial Index (TBI)
9. Confirmed diagnosis of venous insufficiency with duplex ultrasonography to demonstrate reflux of ≥ 0.5 seconds in the superficial lower extremity venous system.

Exclusion Criteria:

1. Index Ulcer is of non-venous pathophysiology
2. Gangrene is present on any part of the affected limb
3. Patient is currently receiving dialysis or planning to go on dialysis
4. Patient has a glycated hemoglobin A1c (HbA1c) level of >12%
5. Chronic oral steroid use >7.5 mg daily for longer than 3 months at the time of screening
6. Patient is receiving IV corticosteroids, immunosuppressive or cytotoxic agents at the time of screening
7. Requiring intravenous (IV) antibiotics to treat the index wound infection at the time of screening
8. Patient has an ulcer within 5 cm of the Index Ulcer identified for study consideration
9. Patient is Human Immunodeficiency Virus (HIV) positive or has Acquired Immune Deficiency Syndrome (AIDS)
10. Current evidence of cellulitis, or other evidence of infection including fever or pus drainage from the wound site
11. Current evidence of osteomyelitis or history of osteomyelitis within 30 days of screening
12. Patient has active malignancy other than non-melanoma skin cancer
13. Patient's Index Ulcer has decreased by ≥ 20% during 1-week screening period
14. Patient's random blood sugar is > 450 mg/dl at screening
15. Patient is unable to receive compression therapy as a part of standard of care
16. Patient has untreated alcohol or substance abuse at the time of screening
17. Pregnant women and women who are breastfeeding
18. Patient is currently enrolled or participated in another investigational device, drug, or biological trial within 30 days of screening
19. Patient has had within the last 30 days, or is currently undergoing, or is planning for wound treatments with growth factors, living skin, dermal substitutes or other advanced biological therapies
20. Patient is an employee, or an immediate family member of an employee, of the sponsor company or site research staff conducting the study
21. Patients who have already been randomized in Protocol 352 at any center may not be considered for screening or for re-entry into the trial at any center, even after the End of Study Visit
22. Patients with a history of poor compliance, or an unwillingness or inability to adhere to the requirements of the protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: TruSkin®; Cryopreserved skin allograft	Other: TruSkin
Active Comparator: Wound Cover; Active Comparator for Venous Leg Ulcers	Other: Wound Cover

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Proportion of patients that achieve a 50% or greater reduction in wound size by 8 weeks	8 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of patients that achieve complete closure of the index wound by 12 weeks	12 weeks
Time to initial wound closure	Up to 84 days
Number of product applications	Up to 84 days
Number of AEs	Up to 84 days
Number of patients with worsening of index wound defined by ≥ 50% increase in wound size	Up to 84 days
Proportion of patients that achieve a 50% or greater reduction in wound size by 4 weeks	4 weeks

Collaborators and Investigators

• Sponsor: Osiris Therapeutics

Study record dates

Study Major Dates

• Study Start: July 1, 2016
• Primary Completion (Actual): April 1, 2017
• Study Completion (Actual): April 1, 2017

Study Registration Dates

• First Submitted: September 20, 2016
• First Submitted That Met QC Criteria: October 14, 2016
• First Posted (Estimate): October 18, 2016

Study Record Updates

• Last Update Posted (Actual): April 6, 2017
• Last Update Submitted That Met QC Criteria: April 4, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Cardiovascular Diseases; Vascular Diseases; Skin Diseases; Skin Ulcer; Varicose Veins; Ulcer; Leg Ulcer; Varicose Ulcer
• Other Study ID Numbers: Osiris Protocol 352

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO